Some patients fear tirzepatide, sold by Eli Lilly under the brand names Zepbound and Mounjaro, will be hard to get and prohibitively expensive once compounding pharmacies are no longer producing it.
Eli Lilly and Co. lowered its full-year guidance Wednesday on lackluster sales of its blockbuster weight-loss drug, a shocking miss for a drugmaker that had been going from strength to strength on ...